WuXi Biologics (Cayman) Inc 2019 AR2
The report highlights WuXi Biologics' outstanding performance in 2019, with robust revenue growth of 57.2% year-on-year and the expansion of its integrated projects pipeline to 250. The company became the first biopharmaceutical company in China to obtain dual GMP certification from both the U.S. FDA and the EU EMA. Additionally, WuXi Biologics launched its state-of-the-art Antibody Drug Conjugates (ADC) facility and entered a strategic vaccine manufacturing partnership valued at over US$3 billion. On the environmental front, the company successfully implemented energy-saving technologies, reducing its electricity consumption intensity by 13.17%.
Company: WuXi Biologics (Cayman) Inc
Sector: Health Care
Country: China
Year: 2019
Type: AR2
Pages: 297
WuXi Biologics (Cayman) Inc
Annual Report
The report highlights WuXi Biologics' outstanding performance in 2019, with robust revenue growth of 57.2% year-on-year and the expansion of its integrated projects pipeline to 250. The company became the first biopharmaceutical company in China to obtain dual GMP certification from both the U.S. FDA and the EU EMA. Additionally, WuXi Biologics launched its state-of-the-art Antibody Drug Conjugates (ADC) facility and entered a strategic vaccine manufacturing partnership valued at over US$3 billion. On the environmental front, the company successfully implemented energy-saving technologies, reducing its electricity consumption intensity by 13.17%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees